 |
 |
David: Entacapone is an experimental drug in development as an adjunct to Sinemet. It is an inhibitor to the enzyme catechol-O-methyl transferase. Inhibiting this enzyme helps prolong the retention of levodopa (the active ingredient of Sinemet) in the blood stream and probalbly in the brain where it is needed for ocnversion to dopamine. The company developing Entacapone is Orion-Farmos. Their headquartes is in Helsinki, Finland. If Entacapone succeeds in its clinical trials, it should start to be available for general use before the end of the 20th century. Sorry to say, but clinical trials and approvals by regulatory authorities take enormous amounts of time. Best regards, Joe Irr